Tag debug info: client: {"assets":{},"datasets":{},"live":{},"projects":{},"users":{},"observable":{"assets":{},"datasets":{},"live":{},"projects":{},"users":{}}} Now: 1770701219548 Cache Key: cqdTagPageBySlug:pembrolizumab fetchCache[cqdTagPageBySlug:pembrolizumab].expirationTime: falsey fetchCache[cqdTagPageBySlug:pembrolizumab]. seconds remaining: falsey All fetchCache expiration times: -- Key: cqdNotFoundPage, seconds remaining: 4602 -- Key: cqdTagPageBySlug:philanthropy, seconds remaining: -7145 -- Key: cqdPostsByTag:cqd-migrated-tag-19564,1,10, seconds remaining: -6994 -- Key: cqdTagPageBySlug:tall-rounds, seconds remaining: -6665 -- Key: cqdPostsByTag:cqd-migrated-tag-4088,1,10, seconds remaining: -6586 -- Key: cqdTagPageBySlug:temporal-lobe-epilepsy, seconds remaining: -1250 -- Key: cqdPostsByTag:cqd-migrated-tag-22401,1,10, seconds remaining: -1178 -- Key: cqdTagPageBySlug:marie-budev, seconds remaining: 1913 -- Key: cqdPostsByTag:cqd-migrated-tag-3596,1,10, seconds remaining: 1997 -- Key: cqdTagPageBySlug:personal-mutanome, seconds remaining: 4602 -- Key: cqdPostsByTag:cqd-migrated-tag-20000,1,10, seconds remaining: 4676 -- Key: cqdTagPageBySlug:nursing-education, seconds remaining: 5043 -- Key: cqdPostsByTag:cqd-migrated-tag-1808,1,10, seconds remaining: 5122 -- Key: cqdTagPageBySlug:trimodality-therapy-tmt, seconds remaining: 5981 -- Key: cqdPostsByTag:cqd-migrated-tag-11452,1,10, seconds remaining: 6060 -- Key: cqdTagPageBySlug:extraperitoneal-radical-prostatectomy, seconds remaining: 7295 -- Key: cqdPostsByTag:cqd-migrated-tag-23765,1,10, seconds remaining: 7382 -- Key: cqdTagPageBySlug:knee-pain, seconds remaining: 8645 -- Key: cqdPostsByTag:cqd-migrated-tag-1321,1,10, seconds remaining: 8729 conditions: -- false, -- NA, -- NA, -- NA -- false Cache miss for key cqdTagPageBySlug:pembrolizumab - retrieving from Sanity CCCache.dataFetchCount: 2135 Cache cleanup seconds remaining: 21913
Advertisement
Advertisement
Pembrolizumab does not improve outcomes, but immunotherapy may still offer benefit
Enfortumab vedotin plus pembrolizumab benefited patients, regardless of biomarker expression
Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy
62% of patients were progression-free at 18 months post-transplantation
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Will cancer vaccine boost immunotherapy’s efficacy?
Immune checkpoint inhibitor and oncolytic viral immunotherapy produce synergistic effect
Enroll patients now in KEYNOTE-630 trial
Another option for immunotherapy
Rendered: Tue Feb 10 2026 05:26:59 GMT+0000 (Coordinated Universal Time)
9500 Euclid Avenue, Cleveland, Ohio 44195 |
800.223.2273 | ©
2026 Cleveland Clinic. All Rights Reserved.
Search
